Table 1.

Summary of Sp1 expression and prognostic significance in tumors

Tumor (ref.)High/lowPrognosis (high Sp) and expression
Pancreatic (40, 57)17/25Increased Sp1 in higher grade (decreased survival)
VariablePoor prognosis – vascular invasion
Glioma (41, 42)130/92Decreased survival
27/28Increased expression in higher grade
Colon (43, 60)Sp1/Sp3 elevated and decreased survival (binding to μPAR)
61/25Increased depth of invasion (inversely correlated with miR-149
Gastric (44–47)VariableIncreased expression in high grades and poor survival
Variable (?)Survival decreased in diffuse type by Sp1; low in most intestinal types
VariableIncreased with stage; decreased survival (correlated with VEGF)
35/30Increased with stage; decreased survival
Head and neck (48)26/26 (Sp3)Increased Sp3 predicted poor survival
Prostate (49)VariableSp1/Sp3/FLIP combination predicted increase recurrence
Lung (50, 51, 58)40/6 (I and II)Lower Sp1 with increasing stage; low Sp1 correlated with poor prognosis
29/43 (IV)
VariableSp1 correlated with CD147 (invasive factor)
Increase Sp1 in tumors
Breast (52–54)43/17Increased invasion, stage and decreased survival
Variable (?)Lower Sp1 with increasing stage
VariableSp1 correlated with CD147
Sp1 predicts poor prognosis
Rhabdomysarcoma (39)Highly overexpressed in tumors
Hepatocellular (55, 56)34/50Overexpressed in tumor
15/25Higher Sp1 – poor prognosis